Search

Your search keyword '"Tran, Phuoc T"' showing total 876 results
Start Over Author "Tran, Phuoc T"
876 results on '"Tran, Phuoc T"'

252. A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer

Author

Yochum, Zachary A., primary, Cades, Jessica, additional, Mazzacurati, Lucia, additional, Neumann, Neil M., additional, Khetarpal, Susheel K., additional, Chatterjee, Suman, additional, Wang, Hailun, additional, Attar, Myriam A., additional, Huang, Eric H.-B., additional, Chatley, Sarah N., additional, Nugent, Katriana, additional, Somasundaram, Ashwin, additional, Engh, Johnathan A., additional, Ewald, Andrew J., additional, Cho, Yoon-Jae, additional, Rudin, Charles M., additional, Tran, Phuoc T., additional, and Burns, Timothy F., additional

Published
2017
Full Text
View/download PDF

253. The Future of Radiobiology

Author

Kirsch, David G, primary, Diehn, Max, additional, Kesarwala, Aparna H, additional, Maity, Amit, additional, Morgan, Meredith A, additional, Schwarz, Julie K, additional, Bristow, Robert, additional, Demaria, Sandra, additional, Eke, Iris, additional, Griffin, Robert J, additional, Haas-Kogan, Daphne, additional, Higgins, Geoff S, additional, Kimmelman, Alec C, additional, Kimple, Randall J, additional, Lombaert, Isabelle M, additional, Ma, Li, additional, Marples, Brian, additional, Pajonk, Frank, additional, Park, Catherine C, additional, Schaue, Dörthe, additional, Tran, Phuoc T., additional, Willers, Henning, additional, Wouters, Brad G., additional, and Bernhard, Eric J, additional

Published
2017
Full Text
View/download PDF

254. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer

Author

Topper, Michael J., primary, Vaz, Michelle, additional, Chiappinelli, Katherine B., additional, DeStefano Shields, Christina E., additional, Niknafs, Noushin, additional, Yen, Ray-Whay Chiu, additional, Wenzel, Alyssa, additional, Hicks, Jessica, additional, Ballew, Matthew, additional, Stone, Meredith, additional, Tran, Phuoc T., additional, Zahnow, Cynthia A., additional, Hellmann, Matthew D., additional, Anagnostou, Valsamo, additional, Strissel, Pamela L., additional, Strick, Reiner, additional, Velculescu, Victor E., additional, and Baylin, Stephen B., additional

Published
2017
Full Text
View/download PDF

256. Pelvic Radiation and Normal Tissue Toxicity

Author

Nicholas, Sarah, primary, Chen, Linda, additional, Choflet, Amanda, additional, Fader, Amanda, additional, Guss, Zachary, additional, Hazell, Sarah, additional, Song, Daniel Y., additional, Tran, Phuoc T., additional, and Viswanathan, Akila N., additional

Published
2017
Full Text
View/download PDF

258. High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer

Author

Kates, Max, primary, Chappidi, Meera R., additional, Brant, Aaron, additional, Milbar, Niv, additional, Sopko, Nikolai A., additional, Meyer, Christian, additional, Terezakis, Stephanie A., additional, Herman, Joseph M., additional, Efron, Jonathan E., additional, Safar, Bashar, additional, Tran, Phuoc T., additional, Ahuja, Nita, additional, Pierorazio, Phillip M., additional, and Bivalacqua, Trinity J., additional

Published
2017
Full Text
View/download PDF

260. Oligoprogression

Author

Rowe, Steven P., primary, Tran, Phuoc T., additional, Fishman, Elliot K., additional, and Johnson, Pamela T., additional

Published
2017
Full Text
View/download PDF

261. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)

Author

Radwan, Noura, primary, Phillips, Ryan, additional, Ross, Ashley, additional, Rowe, Steven P., additional, Gorin, Michael A., additional, Antonarakis, Emmanuel S., additional, Deville, Curtiland, additional, Greco, Stephen, additional, Denmeade, Samuel, additional, Paller, Channing, additional, Song, Daniel Y., additional, Diehn, Maximilian, additional, Wang, Hao, additional, Carducci, Michael, additional, Pienta, Kenneth J., additional, Pomper, Martin G., additional, DeWeese, Theodore L., additional, Dicker, Adam, additional, Eisenberger, Mario, additional, and Tran, Phuoc T., additional

Published
2017
Full Text
View/download PDF

262. TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis

Author

Malek, Reem, primary, Gajula, Rajendra P., additional, Williams, Russell D., additional, Nghiem, Belinda, additional, Simons, Brian W., additional, Nugent, Katriana, additional, Wang, Hailun, additional, Taparra, Kekoa, additional, Lemtiri-Chlieh, Ghali, additional, Yoon, Arum R., additional, True, Lawrence, additional, An, Steven S., additional, DeWeese, Theodore L., additional, Ross, Ashley E., additional, Schaeffer, Edward M., additional, Pienta, Kenneth J., additional, Hurley, Paula J., additional, Morrissey, Colm, additional, and Tran, Phuoc T., additional

Published
2017
Full Text
View/download PDF

263. Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.

Author

Tran, Phuoc T., primary, Moyer, C. Leigh, additional, Phillips, Ryan, additional, Radwan, Noura, additional, Ross, Ashley, additional, Reyes, Diane K., additional, Wright, Jean, additional, Antonarakis, Emmanuel S., additional, Song, Daniel Y., additional, Deville, Curtiland, additional, Walsh, Patrick C., additional, DeWeese, Theodore L., additional, Carducci, Michael Anthony, additional, Schaeffer, Edward M., additional, Pienta, Kenneth J., additional, and Eisenberger, Mario A., additional

Published
2017
Full Text
View/download PDF

264. A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).

Author

Phillips, Ryan, primary, Radwan, Noura, additional, Ross, Ashley, additional, Rowe, Steven P., additional, Gorin, Michael A., additional, Antonarakis, Emmanuel S., additional, Deville, Curtiland, additional, Greco, Stephen C, additional, Denmeade, Samuel R., additional, Paller, Channing Judith, additional, Song, Daniel Y., additional, Diehn, Maximilian, additional, Wang, Hao, additional, Carducci, Michael Anthony, additional, Pienta, Kenneth J., additional, Pomper, Martin G., additional, DeWeese, Theodore L., additional, Dicker, Adam P., additional, Eisenberger, Mario A., additional, and Tran, Phuoc T., additional

Published
2017
Full Text
View/download PDF

269. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

Author

Kim, Jennifer E., primary, Patel, Mira A., additional, Mangraviti, Antonella, additional, Kim, Eileen S., additional, Theodros, Debebe, additional, Velarde, Esteban, additional, Liu, Ann, additional, Sankey, Eric W., additional, Tam, Ada, additional, Xu, Haiying, additional, Mathios, Dimitrios, additional, Jackson, Christopher M., additional, Harris-Bookman, Sarah, additional, Garzon-Muvdi, Tomas, additional, Sheu, Mary, additional, Martin, Allison M., additional, Tyler, Betty M., additional, Tran, Phuoc T., additional, Ye, Xiaobu, additional, Olivi, Alessandro, additional, Taube, Janis M., additional, Burger, Peter C., additional, Drake, Charles G., additional, Brem, Henry, additional, Pardoll, Drew M., additional, and Lim, Michael, additional

Published
2017
Full Text
View/download PDF

271. Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma

Author

Patel, Mira A., primary, Kim, Jennifer E., additional, Theodros, Debebe, additional, Tam, Ada, additional, Velarde, Esteban, additional, Kochel, Christina M., additional, Francica, Brian, additional, Nirschl, Thomas R., additional, Ghasemzadeh, Ali, additional, Mathios, Dimitrios, additional, Harris-Bookman, Sarah, additional, Jackson, Christopher C., additional, Jackson, Christina, additional, Ye, Xiaobu, additional, Tran, Phuoc T., additional, Tyler, Betty, additional, Coric, Vladimir, additional, Selby, Mark, additional, Brem, Henry, additional, Drake, Charles G., additional, Pardoll, Drew M., additional, and Lim, Michael, additional

Published
2016
Full Text
View/download PDF

274. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer

Author

Ross, Ashley E., Hurley, Paula J., Tran, Phuoc T., Rowe, Steven P., Benzon, Benjamin, Neal, Tanya O’, Chapman, Carolyn, Harb, Rana, Milman, Yelena, Trock, Bruce J., Drake, Charles G., and Antonarakis, Emmanuel S.

Abstract

Background: Monotherapy with immune checkpoint inhibitors has generally been unsuccessful in men with advanced prostate cancer. Preclinical data support the notion that cryotherapy may improve immune-mediated and anti-tumor responses. The objective of this study was to assess the safety and feasibility of whole-prostate gland cryotherapy combined with pembrolizumab and androgen deprivation in men with oligometastatic hormone-sensitive prostate cancer. Methods: This single-institution, pilot trial recruited 12 patients with newly diagnosed oligometastatic prostate cancer between 2015 and 2016. Patients underwent whole-prostate cryoablation combined with short-term androgen deprivation (eight months) and pembrolizumab (6 doses). The primary clinical endpoints were the number of patients with a PSA level of <0.6 ng/mL at one year and the frequency of adverse events. Other outcome measures included progression-free survival and systemic therapy-free survival. Exploratory analyses included PD-L1 protein expression. Results: Forty two percent (5/12) of patients had a PSAs of <0.6 ng/mL at one year though only 2 of these patients had recovered their testosterone at this time point. Median progression-free survival was 14 months, and median systemic therapy-free survival was 17.5 months. PD-L1 expression was not detectable by IHC in patients with evaluable tissue. All adverse events were grade ≤2, and there were no apparent complications from cryotherapy. Conclusions: Whole-prostate cryoablation combined with short-term androgen deprivation and pembrolizumab treatment was well tolerated and no safety concerns were observed in men with oligometastatic prostate cancer. Though local disease appeared effectively treated in the majority of men, the regimen only infrequency led to sustained disease control following testosterone recovery.

Published
2020
Full Text
View/download PDF

275. Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer

Author

Deek, Matthew P. and Tran, Phuoc T.

Abstract

Our understanding of metastatic disease is rapidly advancing, with recent evidence supporting an oligometastatic state currently defined by patients having a limited (typically ≤5) number of metastatic deposits. The optimal management of these patients is also shifting toward increased integration of local therapies, with emerging evidence suggesting metastasis-directed therapy can improve overall survival. Additionally, the use of stereotactic ablative radiation therapy within castration-sensitive oligometastatic prostate cancer cohorts appears to forestall the need to initiate systemic therapy, which has unfavorable side effect profiles, such as androgen deprivation therapy, while itself being associated with little toxicity. We review the literature surrounding the use of metastasis-directed therapy in the treatment of oligometastatic prostate cancer by reviewing the evidence for its use within 3 subgroups: de novo synchronous, oligorecurrent, and oligoprogressive disease.

Published
2020
Full Text
View/download PDF

276. Adjuvant radiation with androgen‐deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit.

Author

Gupta, Mohit, Patel, Hiten D., Schwen, Zeyad R., Tran, Phuoc T., and Partin, Alan W.

Subjects
ADJUVANT treatment of cancer, LYMPH node cancer, METASTASIS, PROSTATECTOMY, CANCER radiotherapy
Abstract

Objectives: To perform a comparative analysis of three current management strategies for patients with lymph node metastases (LNM; pN1) following radical prostatectomy (RP): observation, androgen‐deprivation therapy (ADT), and external beam radiation therapy (EBRT) + ADT. Patients and Methods: Patients with LNM after RP were identified using the National Cancer Database (2004–2013). Exclusion criteria included any use of radiation therapy or ADT before RP, clinical M1 disease, or incomplete follow‐up data. Patients were categorised according to postoperative management strategy. The primary outcome was overall survival (OS). Kaplan–Meier curves and adjusted multivariable Cox proportional hazards models were employed. Sub‐analyses further evaluated patient risk stratification and time to receipt of adjuvant therapy. Results: A total of 8 074 patients met the inclusion criteria. Postoperatively, 4 489 (55.6%) received observation, 2 065 (25.6%) ADT, and 1 520 (18.8%) ADT + EBRT. The mean (median; interquartile range) follow‐up was 52.3 (48.0; 28.5–73.5) months. Patients receiving ADT or ADT + EBRT had higher pathological Gleason scores, T‐stage, positive surgical margin rates, and nodal burden. Adjusted multivariable Cox models showed improved OS for ADT + EBRT vs observation (hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.64–0.94; P = 0.008) and vs ADT (HR 0.76, 95% CI: 0.63–0.93; P = 0.007). There was no difference in OS for ADT vs observation (HR 1.01, 95% CI: 0.87–1.18; P = 0.88). Findings were similar when restricting adjuvant cohorts for timing of adjuvant therapy. There was no difference in OS between groups for up to 2 549 (31.6%) patients lacking any of the following adverse features: ≥pT3b disease, Gleason score ≥9, three or more positive nodes, or positive surgical margin. Conclusions: For patients with LNM after RP, the use of adjuvant ADT + EBRT improved OS in the majority of patients, especially those with adverse pathological features. Conversely, adjuvant therapy did not confer significant OS benefit in up to 30% of patients without high‐risk features, who may be managed with observation and forego the morbidity associated with immediate ADT or radiation. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

277. Interactions of Exo1p with components of MutL[Alpha] in Saccharomyces cerevisiae

Author

Tran, Phuoc T., Simon, Jeffrey A., and Liskay, R. Michael

Subjects
Brewer's yeast -- Genetic aspects, Adenosine triphosphatase -- Genetic aspects, Exonucleases -- Genetic aspects, Science and technology
Abstract

Previously, we reported evidence suggesting that Saccharomyces cerevisiae MutL[Alpha], composed of Mlh1p and Pms1p, was a functional member of the gyrase b/Hsp90/MutL (GHL) dimeric ATPase superfamily characterized by highly conserved ATPase domains. Similar to other GHL ATPases, these putative ATPase domains of MutL[Alpha] may be important for the recruitment and/or activation of downstream effectors. One downstream effector candidate is Exo1p, a 5'-3' double stranded DNA exonuclease that has previously been implicated in DNA mismatch repair (MMR). Here we report yeast two-hybrid results suggesting that Exolp can interact physically with MutL[Alpha] through the Mlh1p subunit. We also report epistasis analysis involving MutL[Alpha] ATPase mutations combined with exo1[Delta]. One interpretation of our genetic results is that MutL[Alpha] ATPase domains function to direct Exo1p and other functionally redundant exonucleases during MMR. Finally, our results show that much of the increase in spontaneous mutation observed in an exo1[Delta] strain is REV3-dependent, in turn suggesting that Exo1p is also involved in one or more MMR-independent mutation avoidance pathways.

Published
2001

279. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma

Author

Patel, Mira A., primary, Kim, Jennifer E., additional, Theodros, Debebe, additional, Tam, Ada, additional, Velarde, Esteban, additional, Kochel, Christina M., additional, Francica, Brian, additional, Nirschl, Thomas R., additional, Ghasemzadeh, Ali, additional, Mathios, Dimitrios, additional, Harris-Bookman, Sarah, additional, Jackson, Christopher C., additional, Jackson, Christina, additional, Ye, Xiaobu, additional, Tran, Phuoc T., additional, Tyler, Betty, additional, Coric, Vladimir, additional, Selby, Mark, additional, Brem, Henry, additional, Drake, Charles G., additional, Pardoll, Drew M., additional, and Lim, Michael, additional

Published
2016
Full Text
View/download PDF

281. MP50-18 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN THE EVALUATION OF MEN WITH AN ELEVATED PSA FOLLOWING RADICAL PROSTATECTOMY

Author

Gorin, Michael A., primary, Rowe, Steven P., additional, Mana-ay, Margarita, additional, Szabo, Zsolt, additional, Schaeffer, Edward M., additional, Tran, Phuoc T., additional, Allaf, Mohamad E., additional, Deville, Curtiland, additional, Bivalacqua, Trinity J., additional, Cho, Steve Y., additional, Pomper, Martin G., additional, and Ross, Ashley E., additional

Published
2016
Full Text
View/download PDF

283. Ganetespib radiosensitization for liver cancer therapy

Author

Chettiar, Sivarajan T., primary, Malek, Reem, additional, Annadanam, Anvesh, additional, Nugent, Katriana M., additional, Kato, Yoshinori, additional, Wang, Hailun, additional, Cades, Jessica A., additional, Taparra, Kekoa, additional, Belcaid, Zineb, additional, Ballew, Matthew, additional, Manmiller, Sarah, additional, Proia, David, additional, Lim, Michael, additional, Anders, Robert A., additional, Herman, Joseph M., additional, and Tran, Phuoc T., additional

Published
2016
Full Text
View/download PDF

284. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Author

Wild, Aaron T., primary, Herman, Joseph M., additional, Dholakia, Avani S., additional, Moningi, Shalini, additional, Lu, Yao, additional, Rosati, Lauren M., additional, Hacker-Prietz, Amy, additional, Assadi, Ryan K., additional, Saeed, Ali M., additional, Pawlik, Timothy M., additional, Jaffee, Elizabeth M., additional, Laheru, Daniel A., additional, Tran, Phuoc T., additional, Weiss, Matthew J., additional, Wolfgang, Christopher L., additional, Ford, Eric, additional, Grossman, Stuart A., additional, Ye, Xiaobu, additional, and Ellsworth, Susannah G., additional

Published
2016
Full Text
View/download PDF

286. Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation

Author

Narang, Amol K., primary, Gergis, Carol, additional, Robertson, Scott P., additional, He, Pei, additional, Ram, Ashwin N., additional, McNutt, Todd R., additional, Griffith, Emily, additional, DeWeese, Theodore A., additional, Honig, Stephanie, additional, Singh, Harleen, additional, Song, Danny Y., additional, Tran, Phuoc T., additional, and DeWeese, Theodore L., additional

Published
2016
Full Text
View/download PDF

287. Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk.

Author

Den, Robert, primary, Yousefi, Kasra, additional, Trock, Bruce J., additional, Davicioni, Elai, additional, Tosoian, Jeffrey J., additional, Thompson, Darby J. S., additional, Choeurng, Voleak, additional, Haddad, Zaid, additional, Tran, Phuoc T., additional, Trabulsi, Edouard John, additional, Gomella, Leonard G., additional, Lallas, Costas D., additional, Abdollah, Firas, additional, Feng, Felix Yi-Chung, additional, Dicker, Adam, additional, Freedland, Stephen J., additional, Karnes, Jeffrey, additional, Schaeffer, Edward M., additional, and Ross, Ashley, additional

Published
2016
Full Text
View/download PDF

288. Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.

Author

Tosoian, Jeffrey J., primary, Sundi, Debasish, additional, Chapin, Brian Francis, additional, Antonarakis, Emmanuel S., additional, Chappidi, Meera, additional, Alam, Ridwan, additional, Glavaris, Stephanie, additional, Karnes, R. Jeffrey, additional, Pienta, Kenneth J., additional, Tran, Phuoc T., additional, Schaeffer, Edward M., additional, and Ross, Ashley, additional

Published
2016
Full Text
View/download PDF

289. Study of PSMA-targeted 18F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy.

Author

Gorin, Michael A., primary, Rowe, Steven P., additional, Mana-ay, Margarita, additional, Szabo, Zsolt, additional, Schaeffer, Edward M., additional, Tran, Phuoc T., additional, Allaf, Mohamad E., additional, Deville, Curtiland, additional, Cho, Steve Y., additional, Pienta, Kenneth J., additional, Pomper, Martin G., additional, and Ross, Ashley, additional

Published
2016
Full Text
View/download PDF

290. Effect of local therapy on the systemic anti-tumor response in prostate cancer.

Author

Ross, Ashley, primary, Benzon, Benjamin, additional, Glavaris, Stephanie, additional, Simons, Brian, additional, Hughes, Robert, additional, Mullane, Patrick, additional, Miller, Rebecca, additional, Nugent, Katriana, additional, Shinder, Brian, additional, Blosser, Richard, additional, Tran, Phuoc T., additional, Hurley, Paula, additional, Vuica-Ross, Milena, additional, Schaeffer, Edward M., additional, and Drake, Charles G., additional

Published
2016
Full Text
View/download PDF

292. The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy.

Author

Ross, Ashley, primary, Benzon, Benjamin, additional, Zhao, Shuang, additional, Takhar, Mandeep, additional, Haffner, Michael, additional, Erho, Nicholas, additional, Hurley, Paula, additional, Tosoian, Jeffrey J., additional, Alshalalfa, Mohammed, additional, Glavaris, Stephanie, additional, Simons, Brian, additional, Tran, Phuoc T., additional, Davicioni, Elai, additional, Karnes, Jeffrey, additional, Schaeffer, Edward M., additional, Drake, Charles G., additional, and Feng, Felix Yi-Chung, additional

Published
2016
Full Text
View/download PDF

293. Designing a broad-spectrum integrative approach for cancer prevention and treatment

Author

Block, Keith I., primary, Gyllenhaal, Charlotte, additional, Lowe, Leroy, additional, Amedei, Amedeo, additional, Amin, A.R.M. Ruhul, additional, Amin, Amr, additional, Aquilano, Katia, additional, Arbiser, Jack, additional, Arreola, Alexandra, additional, Arzumanyan, Alla, additional, Ashraf, S. Salman, additional, Azmi, Asfar S., additional, Benencia, Fabian, additional, Bhakta, Dipita, additional, Bilsland, Alan, additional, Bishayee, Anupam, additional, Blain, Stacy W., additional, Block, Penny B., additional, Boosani, Chandra S., additional, Carey, Thomas E., additional, Carnero, Amancio, additional, Carotenuto, Marianeve, additional, Casey, Stephanie C., additional, Chakrabarti, Mrinmay, additional, Chaturvedi, Rupesh, additional, Chen, Georgia Zhuo, additional, Chen, Helen, additional, Chen, Sophie, additional, Chen, Yi Charlie, additional, Choi, Beom K., additional, Ciriolo, Maria Rosa, additional, Coley, Helen M., additional, Collins, Andrew R., additional, Connell, Marisa, additional, Crawford, Sarah, additional, Curran, Colleen S., additional, Dabrosin, Charlotta, additional, Damia, Giovanna, additional, Dasgupta, Santanu, additional, DeBerardinis, Ralph J., additional, Decker, William K., additional, Dhawan, Punita, additional, Diehl, Anna Mae E., additional, Dong, Jin-Tang, additional, Dou, Q. Ping, additional, Drew, Janice E., additional, Elkord, Eyad, additional, El-Rayes, Bassel, additional, Feitelson, Mark A., additional, Felsher, Dean W., additional, Ferguson, Lynnette R., additional, Fimognari, Carmela, additional, Firestone, Gary L., additional, Frezza, Christian, additional, Fujii, Hiromasa, additional, Fuster, Mark M., additional, Generali, Daniele, additional, Georgakilas, Alexandros G., additional, Gieseler, Frank, additional, Gilbertson, Michael, additional, Green, Michelle F., additional, Grue, Brendan, additional, Guha, Gunjan, additional, Halicka, Dorota, additional, Helferich, William G., additional, Heneberg, Petr, additional, Hentosh, Patricia, additional, Hirschey, Matthew D., additional, Hofseth, Lorne J., additional, Holcombe, Randall F., additional, Honoki, Kanya, additional, Hsu, Hsue-Yin, additional, Huang, Gloria S., additional, Jensen, Lasse D., additional, Jiang, Wen G., additional, Jones, Lee W., additional, Karpowicz, Phillip A., additional, Keith, W. Nicol, additional, Kerkar, Sid P., additional, Khan, Gazala N., additional, Khatami, Mahin, additional, Ko, Young H., additional, Kucuk, Omer, additional, Kulathinal, Rob J., additional, Kumar, Nagi B., additional, Kwon, Byoung S., additional, Le, Anne, additional, Lea, Michael A., additional, Lee, Ho-Young, additional, Lichtor, Terry, additional, Lin, Liang-Tzung, additional, Locasale, Jason W., additional, Lokeshwar, Bal L., additional, Longo, Valter D., additional, Lyssiotis, Costas A., additional, MacKenzie, Karen L., additional, Malhotra, Meenakshi, additional, Marino, Maria, additional, Martinez-Chantar, Maria L., additional, Matheu, Ander, additional, Maxwell, Christopher, additional, McDonnell, Eoin, additional, Meeker, Alan K., additional, Mehrmohamadi, Mahya, additional, Mehta, Kapil, additional, Michelotti, Gregory A., additional, Mohammad, Ramzi M., additional, Mohammed, Sulma I., additional, Morre, D. James, additional, Muralidhar, Vinayak, additional, Muqbil, Irfana, additional, Murphy, Michael P., additional, Nagaraju, Ganji Purnachandra, additional, Nahta, Rita, additional, Niccolai, Elena, additional, Nowsheen, Somaira, additional, Panis, Carolina, additional, Pantano, Francesco, additional, Parslow, Virginia R., additional, Pawelec, Graham, additional, Pedersen, Peter L., additional, Poore, Brad, additional, Poudyal, Deepak, additional, Prakash, Satya, additional, Prince, Mark, additional, Raffaghello, Lizzia, additional, Rathmell, Jeffrey C., additional, Rathmell, W. Kimryn, additional, Ray, Swapan K., additional, Reichrath, Jörg, additional, Rezazadeh, Sarallah, additional, Ribatti, Domenico, additional, Ricciardiello, Luigi, additional, Robey, R. Brooks, additional, Rodier, Francis, additional, Rupasinghe, H.P. Vasantha, additional, Russo, Gian Luigi, additional, Ryan, Elizabeth P., additional, Samadi, Abbas K., additional, Sanchez-Garcia, Isidro, additional, Sanders, Andrew J., additional, Santini, Daniele, additional, Sarkar, Malancha, additional, Sasada, Tetsuro, additional, Saxena, Neeraj K., additional, Shackelford, Rodney E., additional, Shantha Kumara, H.M.C., additional, Sharma, Dipali, additional, Shin, Dong M., additional, Sidransky, David, additional, Siegelin, Markus David, additional, Signori, Emanuela, additional, Singh, Neetu, additional, Sivanand, Sharanya, additional, Sliva, Daniel, additional, Smythe, Carl, additional, Spagnuolo, Carmela, additional, Stafforini, Diana M., additional, Stagg, John, additional, Subbarayan, Pochi R., additional, Sundin, Tabetha, additional, Talib, Wamidh H., additional, Thompson, Sarah K., additional, Tran, Phuoc T., additional, Ungefroren, Hendrik, additional, Vander Heiden, Matthew G., additional, Venkateswaran, Vasundara, additional, Vinay, Dass S., additional, Vlachostergios, Panagiotis J., additional, Wang, Zongwei, additional, Wellen, Kathryn E., additional, Whelan, Richard L., additional, Yang, Eddy S., additional, Yang, Huanjie, additional, Yang, Xujuan, additional, Yaswen, Paul, additional, Yedjou, Clement, additional, Yin, Xin, additional, Zhu, Jiyue, additional, and Zollo, Massimo, additional

Published
2015
Full Text
View/download PDF

294. Developments in oligometastatic hormone-sensitive prostate cancer.

Author

Tran, Phuoc T. and Ost, Piet

Subjects
*CASTRATION-resistant prostate cancer, *PROSTATE cancer
Abstract

Newer and highly sensitive imaging modalities for prostate cancer cannot be ignored and will be a critical bridge towards a molecular definition of oligometastatic prostate cancer [[11]]. Pasoglou et al. then present some original work using whole-body magnetic resonance imaging (WB-MRI) to assess the anatomical distribution of oligometastatic and polymetastatic prostate cancer and the impact of the initial treatment on metastatic distribution [[13]]. In the modern era with conventional imaging, metastatic prostate cancer as a whole is only a minority of newly diagnosed cases making I synchronous i or de novo oligometastatic prostate cancer an even smaller subset of these men. Nonetheless, this is an exciting and important clinical space where Nicholas Nickols and his group review the existing data evaluating primary tumor therapy for patients with metastatic prostate cancer and describe ongoing clinical trials testing the hypothesis that primary tumor therapy may benefit patients with metastatic prostate cancer [[14]]. [Extracted from the article]

Published
2019
Full Text
View/download PDF

295. Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses

Author

Zeng, Jing, Harris, Timothy J., Lim, Michael, Drake, Charles G., and Tran, Phuoc T.

Subjects
Article Subject
Abstract

New and innovative treatment strategies for cancer patients in the fields of immunotherapy and radiotherapy are rapidly developing in parallel. Among the most promising preclinical treatment approaches is combining immunotherapy with radiotherapy where early data suggest synergistic effects in several tumor model systems. These studies demonstrate that radiation combined with immunotherapy can result in superior efficacy for local tumor control. More alluring is the emergence of data suggesting an equally profound systemic response also known as “abscopal” effects with the combination of radiation and certain immunotherapies. Studies addressing optimal radiation dose, fractionation, and modality to be used in combination with immunotherapy still require further exploration. However, recent anecdotal clinical reports combining stereotactic or hypofractionated radiation regimens with immunotherapy have resulted in dramatic sustained clinical responses, both local and abscopal. Technologic advances in clinical radiation therapy has made it possible to deliver hypofractionated regimens anywhere in the body using stereotactic radiation techniques, facilitating further clinical investigations. Thus, stereotactic radiation in combination with immunotherapy agents represents an exciting and potentially fruitful new space for improving cancer therapeutic responses.

Published
2013
Full Text
View/download PDF

296. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Author

Kishan, Amar U., Cook, Ryan R., Ciezki, Jay P., Ross, Ashley E., Pomerantz, Mark M., Nguyen, Paul L., Shaikh, Talha, Tran, Phuoc T., Sandler, Kiri A., Stock, Richard G., Merrick, Gregory S., Demanes, D. Jeffrey, Spratt, Daniel E., Abu-Isa, Eyad I., Wedde, Trude B., Lilleby, Wolfgang, Krauss, Daniel J., Shaw, Grace K., Alam, Ridwan, and Reddy, Chandana A.

Subjects
PROSTATE cancer treatment, PROSTATECTOMY, GLEASON grading system, PROSTATE cancer prognosis, PROSTATE cancer patients, CANCER radiotherapy, PROSTATE surgery, RADIOISOTOPE brachytherapy, ANTIANDROGENS, PROSTATE tumors treatment, COMBINED modality therapy, COMPARATIVE studies, CAUSES of death, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, METASTASIS, PROBABILITY theory, PROSTATE tumors, RADIOTHERAPY, RESEARCH, RESEARCH funding, SURVIVAL analysis (Biometry), TUMOR classification, EVALUATION research, RETROSPECTIVE studies, DISEASE progression, TUMOR grading, THERAPEUTICS
Abstract

Importance: The optimal treatment for Gleason score 9-10 prostate cancer is unknown.Objective: To compare clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.Design, Setting, and Participants: Retrospective cohort study in 12 tertiary centers (11 in the United States, 1 in Norway), with 1809 patients treated between 2000 and 2013.Exposures: Radical prostatectomy (RP), external beam radiotherapy (EBRT) with androgen deprivation therapy, or EBRT plus brachytherapy boost (EBRT+BT) with androgen deprivation therapy.Main Outcomes and Measures: The primary outcome was prostate cancer-specific mortality; distant metastasis-free survival and overall survival were secondary outcomes.Results: Of 1809 men, 639 underwent RP, 734 EBRT, and 436 EBRT+BT. Median ages were 61, 67.7, and 67.5 years; median follow-up was 4.2, 5.1, and 6.3 years, respectively. By 10 years, 91 RP, 186 EBRT, and 90 EBRT+BT patients had died. Adjusted 5-year prostate cancer-specific mortality rates were RP, 12% (95% CI, 8%-17%); EBRT, 13% (95% CI, 8%-19%); and EBRT+BT, 3% (95% CI, 1%-5%). EBRT+BT was associated with significantly lower prostate cancer-specific mortality than either RP or EBRT (cause-specific HRs of 0.38 [95% CI, 0.21-0.68] and 0.41 [95% CI, 0.24-0.71]). Adjusted 5-year incidence rates of distant metastasis were RP, 24% (95% CI, 19%-30%); EBRT, 24% (95% CI, 20%-28%); and EBRT+BT, 8% (95% CI, 5%-11%). EBRT+BT was associated with a significantly lower rate of distant metastasis (propensity-score-adjusted cause-specific HRs of 0.27 [95% CI, 0.17-0.43] for RP and 0.30 [95% CI, 0.19-0.47] for EBRT). Adjusted 7.5-year all-cause mortality rates were RP, 17% (95% CI, 11%-23%); EBRT, 18% (95% CI, 14%-24%); and EBRT+BT, 10% (95% CI, 7%-13%). Within the first 7.5 years of follow-up, EBRT+BT was associated with significantly lower all-cause mortality (cause-specific HRs of 0.66 [95% CI, 0.46-0.96] for RP and 0.61 [95% CI, 0.45-0.84] for EBRT). After the first 7.5 years, the corresponding HRs were 1.16 (95% CI, 0.70-1.92) and 0.87 (95% CI, 0.57-1.32). No significant differences in prostate cancer-specific mortality, distant metastasis, or all-cause mortality (≤7.5 and >7.5 years) were found between men treated with EBRT or RP (cause-specific HRs of 0.92 [95% CI, 0.67-1.26], 0.90 [95% CI, 0.70-1.14], 1.07 [95% CI, 0.80-1.44], and 1.34 [95% CI, 0.85-2.11]).Conclusions and Relevance: Among patients with Gleason score 9-10 prostate cancer, treatment with EBRT+BT with androgen deprivation therapy was associated with significantly better prostate cancer-specific mortality and longer time to distant metastasis compared with EBRT with androgen deprivation therapy or with RP. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

297. Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop.

Author

Marciscano, Ariel E., Walker, Joshua M., McGee, Heather M., Kim, Michelle M., Kunos, Charles A., Monjazeb, Arta M., Shiao, Stephen L., Tran, Phuoc T., and Ahmed, Mansoor M.

Subjects
CANCER radiotherapy, CANCER immunotherapy, IMMUNE response
Abstract

Radiotherapy (RT) has been a fundamental component of the anti-cancer armamentarium for over a century. Approximately half of all cancer patients are treated with radiotherapy during their disease course. Over the two past decades, there has been a growing body of preclinical evidence supporting the immunomodulatory effects of radiotherapy, particularly when combined with immunotherapy, but only anecdotal clinical examples existed until recently. The renaissance of immunotherapy and the recent U.S. Food and Drug Administration (FDA) approval of several immune checkpoint inhibitors (ICIs) and other immuno-oncology (IO) agents in multiple cancers provides the opportunity to investigate how localized radiotherapy can induce systemic immune responses. Early clinical experiences have demonstrated feasibility of this approach but additional preclinical and clinical investigation is needed to understand how RT and immunotherapy can be optimally combined. To address questions that are critical to successful incorporation of radiation oncology into immunotherapy, the American Society for Radiation Oncology (ASTRO), the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI) organized a collaborative scientific workshop, Incorporating Radiation Oncology into Immunotherapy, that convened on June 15 and 16 of 2017 at the Natcher Building, NIH Campus in Bethesda, Maryland. This report summarizes key data and highlights from each session. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

299. Transcriptomic heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.

Author

Sutera, Philip, Shetty, Amol, Hakansson, Alexander K., Van der Eecken, Kim, Song, Yang, Liu, Yang, Fonteyne, Valerie, Verbeke, Sofie, Song, Daniel Y., Ross, Ashley, Feng, Felix Y, Gillessen, Silke, Attard, Gerhardt, James, Nicholas D., Lotan, Tamara L., Davicioni, Elai, Sweeney, Christopher, Tran, Phuoc T., Deek, Matthew Pierre, and Ost, Piet

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results